Skip to main navigation Skip to search Skip to main content

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines

  • Maarten G. Lansberg
  • , Martin J. Ó Donnell
  • , Pooja Khatri
  • , Eddy S. Lang
  • , Mai N. Nguyen-Huynh
  • , Neil E. Schwartz
  • , Frank A. Sonnenberg
  • , Sam Schulman
  • , Per Olav Vandvik
  • , Frederick A. Spencer
  • , Pablo Alonso-Coello
  • , Gordon H. Guyatt
  • , Elie A. Akl
  • Stanford University
  • University of Cincinnati College of Medicine
  • Univ. of Calgary
  • University of California San Francisco
  • Rutgers Robert Wood Johnson Medical School at New Brunswick
  • McMaster University
  • Norwegian Knowledge Centre for the Health Services
  • St Joseph's Healthcare
  • Iberoamerican Cochrane Centre
  • State University of New York at Buffalo

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

433 Citations (Scopus)

Abstract

Objectives: This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). Methods: We generated treatment recommendations (Grade 1) and suggestions (Grade 2) based on high (A), moderate (B), and low (C) quality evidence. Results: In patients with acute ischemic stroke, we recommend IV recombinant tissue plasminogen activator (r-tPA) if treatment can be initiated within 3 h (Grade 1A) or 4.5 h (Grade 2C) of symptom onset; we suggest intraarterial r-tPA in patients ineligible for IV tPA if treatment can be initiated within 6 h (Grade 2C); we suggest against the use of mechanical thrombectomy (Grade 2C) although carefully selected patients may choose this intervention; and we recommend early aspirin therapy at a dose of 160 to 325 mg (Grade 1A). In patients with acute stroke and restricted mobility, we suggest the use of prophylactic-dose heparin or intermittent pneumatic compression devices (Grade 2B) and suggest against the use of elastic compression stockings (Grade 2B). In patients with a history of noncardioembolic ischemic stroke or TIA, we recommend long-term treatment with aspirin (75-100 mg once daily), clo pidogrel (75 mg once daily), aspirin/extended release dipyridamole (25 mg/200 mg bid), or cilostazol (100 mg bid) over no antiplatelet therapy (Grade 1A), oral anticoagulants (Grade 1B), the combination of clopidogrel plus aspirin (Grade 1B), or triflusal (Grade 2B). Of the recommended antiplatelet regimens, we suggest clopidogrel or aspirin/extended-release dipyridamole over aspirin (Grade 2B) or cilostazol (Grade 2C). In patients with a history of stroke or TIA and atrial fibrillation we recommend oral anticoagulation over no antithrombotic therapy, aspirin, and combination therapy with aspirin and clopidogrel (Grade 1B). Conclusion: These recommendations can help clinicians make evidence-based treatment decisions with their patients who have had strokes.

Original languageEnglish
Pages (from-to)e601S-e636S
JournalChest
Volume141
Issue number2 SUPPL.
DOIs
Publication statusPublished - Feb 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines'. Together they form a unique fingerprint.

Cite this